The drugs attack so-called amyloid plaques in the brain. But how can we reliably and cost effectively diagnose the presence of amyloid plaques in patients who show up at memory clinics with slight ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

ATTR amyloidosis results from the buildup of transthyretin in the body. It can be inherited or acquired and can affect your heart, kidneys, and nervous system. While there’s no cure, treatment ...

View all available purchase options and get full access to this article.

Repeat MRI another 9 months later showed resolution of many of the parenchymal abnormalities, but with several new regions containing more peripheral microbleeds. Amyloid-PET (using 18 F-florbetapir) ...

Suggested remit: To appraise the clinical and cost effectiveness of eplontersen within its marketing authorisation for treating polyneuropathy caused by hereditary transthyretin amyloidosis.

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

Eplontersen is recommended, within its marketing authorisation, as an option for treating hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy. It is only ...

Cardiac amyloidosis is becoming increasingly recognized as an etiology for heart failure (HF). Most cases of amyloid cardiomyopathy will fall into one of two categories: light-chain amyloid (AL) ...